10 Best Marijuana Stocks To Buy According to Hedge Funds

7. Aurora Cannabis Inc. (NASDAQ:ACB)

Number of Hedge Fund Holders: 6

Aurora Cannabis Inc. (NASDAQ:ACB) engages in the production, distribution, and sale of cannabis and cannabis-derived products across Canada, Europe, Australia, and South America. Since 2006, the company has developed more than 200 different medical products and is the leading provider of medical cannabis to Canadian patients – a market worth over $250 million in fiscal year 2023-24. The Edmonton-based producer has transformed itself from a Canadian recreational player into an international medical-cannabis powerhouse.

Aurora Cannabis Inc. (NASDAQ:ACB) had a strong Q2 2025, with a total net revenue of $81.1 million, up from $63.1 million in the same period last year. Medical marijuana, which is its core segment, grew 41% YoY to reach $61.3 million. The company’s strategy of going global also seems to be paying off, as its international revenue increased 93% to $35 million, exceeding Canadian medical revenue for the first time and contributing 57% to total global medical cannabis revenue. Aurora is now number two in Australia, which is emerging as the largest medical cannabis market in the world outside of North America, sized at around $250 million annually according to the Pennington Institute. Germany also posted significant growth since the country adopted one of the most liberal legal approaches to cannabis in Europe.

As a result, Aurora Cannabis Inc. (NASDAQ:ACB) reported a net profit of $1.7 million in the last quarter, a notable YoY increase of 325%. This means that the company managed to report quarterly earnings of $0.04 per share, beating analysts’ estimates of a loss of $0.22 per share and topping consensus revenue estimates three times over the last four quarters. Aurora also ended the quarter with approximately $152 million in cash and cash equivalents and no debt in its cannabis business.

Aurora Cannabis Inc. (NASDAQ:ACB)’s focus on innovation and research, expanding international footprint, and debt-free balance sheet provides it a concrete edge over its competitors in the rapidly ballooning medical marijuana industry.